socalTECH

OCTOBER 21, 2013

San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced.

Arcturus 153

Arcturus San Diego .Net Venture Capital 153

socalTECH

MAY 16, 2011

Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. Arcturus first invested in Pliant in 2007. SanDisk is a major manufacturer of flash memory.

Arcturus 150

Arcturus Pasadena Venture Capital Equity 150

socalTECH

JUNE 3, 2013

San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech'

Arcturus 138

Arcturus San Diego .Net Venture Capital 138

socalTECH

NOVEMBER 9, 2020

San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds.

Arcturus 113

Arcturus Study San Diego Funding 113

socalTECH

NOVEMBER 17, 2022

Los Angeles-based Arcturus, a developer of 3D video editing tools, said Wednesday afternoon that it has raised $11M in a Series A funding round. The funding was led by Cloudtree Ventures, and also included Autodesk and Epic Games. The startup is led by CEO Kamal Mistry.

Arcturus 100

Arcturus Tool Los Angeles Content 100

Xconomy

FEBRUARY 9, 2018

A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. But the results, touted as positive, left more questions than answers.

Help 58

Help Develop Development Arcturus 58